Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research

• DOI: 10.1007/s00417-013-2562-6
• Publication Date: 2014-01-14T06:24:37Z
• Authors: Armin Wolf; Anselm Kampik
• Keywords: Pro re nata; Tolerability

To assess healthcare processes during treatment of neovascular age-related macular degeneration (AMD) in patients under real-life conditions and evaluate efficacy monthly visual acuity (VA) assessment a pro re nata regime.A multicentre, prospective, non-interventional study based Germany included AMD treated with intravitreal ranibizumab. Patients completed 3-month loading phase injections 0.5 mg ranibizumab, followed by 12-month maintenance which investigators documented VA, additional injections, metamorphopsias, routine ophthalmological examinations adverse events at follow-up visits. Efficacy analysis change from baseline best-corrected VA (BCVA) on descriptive statistics.A total 2,232 were enrolled throughout 1,729 (mean age 77.8 years, 63.2 % women) comprised the population complete set data. In clinical setting recorded our study, only minority underwent optical coherence tomography (71 patients). received mean 4.5 injections; three upload 1.5 phase. Over half (51.4 %) did not receive injections. Mean decimal BCVA increased phase, (from LogMAR 0.201 to 0.219 Month 4) but displayed decline over time (0.192 15).Ranibizumab demonstrated patients, as shown initial gains BCVA. However, improvement these remained below those expected compared MARINA, ANCHOR CATT trials, most likely due low number retreatments, high poor response regard improvements who investigated studies.This IV health services research was conducted Novartis internal registration code, CRFB002ADE10.